Frontlight ResearchEarly access
What researchers published on Fabry disease
289 papers, newest first.
Showing 5 of 5
Randomised trialPopulation Pharmacokinetic Modeling for the Iminosugar Lucerastat Supports Dose Adaptation in Patients With Fabry Disease and Moderate to Severe Renal Function Impairment.Journal of clinical pharmacology
In plain wordsRead moreRead the paper on PubMedTrial resultLong-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.Orphanet journal of rare diseases
In plain wordsRead moreRead the paper on PubMedRandomised trialLucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension.Nature communications
In plain wordsRead moreRead the paper on PubMedRandomised trialHistorical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease.Molecular genetics & genomic medicine
Randomised trialAscorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study.Journal of magnetic resonance imaging : JMRI